TriSalus Life Sciences Signals Confident Growth Path

Trisalus Life Sciences, Inc. ((TLSI)) has held its Q4 earnings call. Read on for the main highlights of the call.

TriSalus Life Sciences’ latest earnings call carried a clearly upbeat tone, with management highlighting strong double‑digit revenue growth, improving margins, and a pivotal capital raise that extends the company’s runway. While acknowledging delays in key clinical data and execution risks around a rapid commercial ramp, executives framed these as manageable timing issues rather than structural setbacks.

Strong Top-Line Growth and Early Achievement of 2025 Targets

TriSalus reported Q4 revenue of $13.2 million, up 60% year over year from $8.3 million, reflecting accelerating adoption of its interventional oncology and embolization technologies. Full‑year revenue climbed 53% to $45.2 million, and management noted that this performance effectively delivered on the company’s 2025 growth objectives ahead of schedule.

Improved Profitability Metrics in the Fourth Quarter

Profitability trends moved in the right direction, with Q4 gross margin improving to 87% from 85% in the prior‑year period as scale and mix effects kicked in. The net operating loss narrowed sharply to $3.3 million from $7.6 million, while adjusted EBITDA loss improved to roughly $0.95 million compared with a $5.7 million loss a year earlier.

Demonstrating Operating Leverage Over the Full Year

Full‑year operating loss fell to $26.9 million from $36.2 million, underscoring emerging operating leverage as revenue and gross profit expand faster than expenses. Gross profit rose by $12.9 million year over year, signaling that the company is converting top‑line gains into better bottom‑line performance despite ongoing investment.

Oversubscribed Capital Raise Strengthens Balance Sheet

To support its growth plans, TriSalus completed an oversubscribed public offering in February that raised $46 million in gross proceeds, more than double the amount initially targeted. The company also added veteran healthcare investor Michael Stansky to its board, bolstering both financial flexibility and governance as it scales commercial and clinical activities.

Commercial Portfolio Expansion and New Product Launches

Management spotlighted a rapid expansion of the commercial portfolio from two core offerings at the start of 2025 to an expected seven differentiated products in 2026. Recent launches include TriNav LV, TriGuide, TriNav FLX, and TriNav XP, while TriNav Advance awaits regulatory clearance, with an initial launch planned for the first half of 2026 and a broader rollout in the second half.

Growing Market Opportunity and Reimbursement Tailwinds

The company sized its liver embolization total addressable market at roughly $480 million, with the broader embolization market estimated around $2.3 billion, framing a sizable runway for growth. A key reimbursement win came as CMS introduced HCPCS code C8004, which expands coverage for mapping and simulation procedures and effectively doubles reimbursable usage in the radioembolization segment.

Encouraging Early Clinical and Registry Data

TriSalus highlighted preliminary thyroid results from its PROTECT registry, reporting 100% technical and clinical success, no neurovascular complications, and a 73% median reduction in thyroid size. Normalization of thyroid function occurred in 71% of participants, with only mild, transient discomfort in most cases, and the company has now initiated a pilot GAE registry while preparing a broader GAE clinical trial registry.

Maintaining Cost and R&D Discipline

Research and development spending trended lower, with Q4 R&D at $2.6 million versus roughly $3.0 million in the prior‑year quarter and full‑year R&D down by about $2.7 million. Management attributed the decline to the completion of PERIO clinical studies and a substantial reduction in internal spending on nelitolimod, reflecting a focus on preserving capital while prioritizing commercial execution.

Delay in Nelitolimod Data Consolidation

One notable negative was a delay in the planned clinical data update for nelitolimod from the PERIO program, which had been expected in Q4 2025. Management has pushed this to the second half of 2026 to consolidate data across three Phase I studies and include external investigator‑initiated results, stressing that the timing shift is not driven by safety or efficacy issues.

Temporary Gross Margin Pressure From Manufacturing Ramp

Despite the stronger Q4 margin, full‑year gross margin dipped slightly to 85% from 86% as manufacturing inefficiencies weighed on results earlier in 2025. These headwinds were tied to scaling production of new products launched in the second and third quarters, with management pointing to visible improvement in the fourth quarter as processes stabilized.

One-Time G&A Charges Lift Annual Overheads

General and administrative expenses rose by $3.5 million year over year, driven partly by a $1.6 million accelerated non‑cash stock‑based compensation charge. A reclassification of roughly $700,000 in patent‑related expenses from R&D to G&A also contributed, signaling that a portion of the G&A increase reflects accounting and one‑time items rather than ongoing cost creep.

Higher GAAP Loss Per Share From Capital Structure Changes

Basic and diluted loss per share deteriorated to $1.84 from $1.31, a move management linked primarily to the conversion of preferred stock to common shares. While the underlying operating losses narrowed, the larger share count diluted per‑share metrics, a trade‑off investors will weigh against the benefits of a simplified capital structure.

Year-End Cash and Dependence on New Financing

TriSalus ended 2025 with $20.4 million in cash and cash equivalents, a level that underscored the importance of the subsequent equity raise. The $46 million gross offering completed in February materially extends the company’s funding runway, but also highlights that continued growth depends on balancing investment needs against dilution and future capital access.

Execution and Timing Risks Around Commercial Ramp

Management flagged that near‑term execution risk remains as the company virtually doubles its commercial footprint and realigns territories, onboarding and training new sales personnel. Revenue in 2026 is expected to be weighted roughly 40% in the first half and 60% in the second half, and the timing of TriNav Advance clearance and rollout adds another variable, prompting the company to withhold specific EBITDA or cash flow breakeven targets.

Forward-Looking Guidance and Growth Outlook

The company reaffirmed 2026 revenue guidance of $60 million to $62 million, implying continued solid growth from the $45.2 million posted in 2025 as the portfolio expands to seven products and the enlarged salesforce gains traction. Management also pointed to large addressable markets, pending health economics and multi‑indication data in 2026, and a consolidated nelitolimod update in the second half of the year as potential catalysts.

TriSalus’ earnings call sketched a picture of a company transitioning from early commercialization toward scale, with robust revenue growth, better margins, and fresh capital underpinning a constructive outlook. Investors will be watching closely to see whether management can execute on the expanded product launches and sales build‑out while navigating clinical data timelines and preserving the improving profitability trends.